Evasc Neurovascular of Vancouver closed a $7.5 million Series A venture round, led by Yonghua Capital of Shanghai. Evasc is developing a patented aneurysm treatment device, called eCLIPs, that Evasc believes will prove to be effective in 95% of all aneurysm cases. So far, the device has been implanted in 40 patients. The latest round, which includes participation from several of Evasc's existing investors, brings Evasc's total funding raised to date to $21 million.
